Duloxetine is a serotonin and norepinephrine reuptake inhibitor (SNRI), first patented in 1990 and marketed in the United States in 2004. It is FDA-approved for use in the treatment of major depressive disorder, generalized anxiety disorder, fibromyalgia, chronic musculoskeletal pain, and diabetic peripheral neuropathy. Off-label (non-FDA approved) use for duloxetine include chemotherapy-induced peripheral neuropathy and stress urinary incontinence in both men and women.
In addition to its general SNRI properties, duloxetine has also been shown to increase dopamine levels, specifically in the prefrontal cortex. Due to the involvement of the prefrontal cortex in depression, the actions of duloxetine in this region also contribute to its efficacy in the treatment of depression. However, the mechanism of action does not involve the inhibition of dopamine transporters.
Duloxetine inhibits the reuptake of both serotonin and norepinephrine, thus combining two therapeutic mechanisms in one agent to treat depression and anxiety. As well, duloxetine has been shown to enhance dopamine levels within the prefrontal cortex. The mechanism of action behind the increase in dopamine levels involves the inhibition of norepinephrine transporters. These transporters have been shown to have a significant affinity for dopamine, resulting in the pump’s ability to act on both dopamine and norepinephrine. Therefore, inhibition of norepinephrine transporters can lead to an increase in dopamine. This increase in dopamine specifically takes place in the prefrontal cortex where dopamine transporters are scarce, and reuptake relies more heavily on norepinephrine transporters.
Duloxetine works to treat various neuropathic and chronic pain states by increasing the activity of noradrenergic and serotonergic neurons in the descending spinal pathway on the dorsal horn. These descending neurons inhibit the activity of dorsal horn neurons, suppressing excessive input from reaching the brain. The hypothesis is that a deficiency in these inhibitory signals results in excess input reaching the brain, which gets perceived as pain.
Of note, duloxetine has no significant activity for muscarinic, cholinergic, alpha2-adrenergic, or H1 histaminergic receptors.
Duloxetine is most commonly administered in a capsule form due to good absorption via the oral route, and administration can be with or without food. Duloxetine should not be crushed or chewed. However, studies have shown that duloxetine may remain stable up to 2 hours after being opened and sprinkled on apple juice or apple sauce.
Management of fibromyalgia: 30mg once daily can be given for one week, then the dose may be increased to 60 mg once daily. A titration approach may also be utilized starting with 20 mg once daily, then increasing the dose by 20 mg every week, up to 60 mg, as tolerated. Maximum dose: 60 mg/day.
Treatment of generalized anxiety disorder (GAD): 60mg can be administered initially, however depending on patient tolerance, 30 mg may be given once daily for one week, then the dose may be increased to 60mg once daily. Though studies have shown no additional benefit to dose above 60 mg/day, some experts have reported benefit when increasing dose over 60 mg/day.
Treatment of unipolar major depressive disorder (MDD): 40 to 60 mg/day can be given in a single or two divided doses. It may be necessary to start at 30mg/day for one week, and then the dose may be increased to 60 mg/day. Maintenance: 60 mg/day. Though studies have shown no additional benefit to dose above 60 mg/day, some experts have reported benefit when increasing dose over 60 mg/day.
Management of pain associated with diabetic peripheral neuropathy: 60 mg can be administered initially, however depending on patient tolerance, lower starting doses may be appropriate. Maximum dose: 60 mg/day.
Management of chronic musculoskeletal pain, including osteoarthritis of the knee and low back pain:
Low back pain: 30 mg can be given once daily for one week and increased up to 60 mg once daily as tolerated as an adjunct therapy. Maximum dose: 60 mg/day.
Knee pain: 30 mg can be given once daily for one week and increased up to 60 mg once daily as tolerated as an adjunct therapy.
Duloxetine has a very low anticholinergic side effect profile; adverse effects related to the cardiovascular, gastrointestinal, central nervous system, such as headache and drowsiness, and fatigue are more common.
Serious adverse effects of duloxetine include:
Common adverse effects of duloxetine include:
Duloxetine is contraindicated in patients with concurrent or recent (within two weeks) therapy with a monoamine oxidase (MAO) inhibitors, uncontrolled acute-angle glaucoma, or hypersensitivity to duloxetine. As well, duloxetine should be avoided in patients receiving treatment with linezolid or IV methylene blue due to an increased risk of serotonin syndrome.
Use in Special Populations:
Duloxetine is FDA pregnancy category C, which means risk to fetal development cannot be ruled out. In animal reproductive studies, duloxetine was shown to have adverse effects on embryo/fetal development. Therefore, the clinician should only give duloxetine if the potential benefits justify the potential risk to the fetus.
Duloxetine is excreted in breast milk and may produce effects in the nursing infant. Some studies show the relative infant dose (RID) of duloxetine to be 2.3%. RID is the dose received via breast milk relative to the mother’s dose. A RID below 10% is acceptable when breastfeeding. Some sources recommend breastfeeding only if RID less than 5% if the mother is on psychotropic medication. Regardless, an infant breastfed by a mother receiving duloxetine requires monitoring for behavior changes, sleep disturbance, feeding changes, growth, and neurodevelopment.
SSRIs and SNRIs have correlations with several cases of clinically significant hyponatremia in elderly adults. Caution is necessary when prescribing duloxetine in the geriatric population. However, dosage adjustment based on the age of the patient is not required.
Blood pressure and vitals should be checked before initiating therapy and routinely thereafter. Monitor for changes in suicidal ideation, especially when starting treatment, dosage changes, and after discontinuation. Monitor for worsening depression, behavioral changes such as mania, and withdrawal symptoms from abrupt discontinuation. Labs that require monitoring including creatinine, BUN, and transaminase levels as well as blood glucose levels and HgbA1c in diabetic patients. Sodium levels require followup when prescribing duloxetine in the geriatric population.
Fatal outcomes have occurred with overdoses at as low as 1000 mg. Signs and symptoms of overdose include serotonin syndrome, seizures, coma, somnolence, syncope, tachycardia, autonomic instability, diarrhea, and vomiting.
Signs of serotonin syndrome include agitation, restless, disorientation, diaphoresis, hyperthermia, tachycardia, nausea, vomiting, tremor, muscle rigidity, hyperreflexia, myoclonus, dilated pupils, dry mucous membranes, and increased bowel sounds. Clonus and hyperreflexia are particularly common in serotonin syndrome.
There is no antidote to duloxetine overdose. However, cyproheptadine and cooling measures may be a consideration if the patient is presenting with serotonin syndrome. Patients with abnormal vital signs need monitoring, and severe cases may warrant ICU-level of care.
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Close observation and routine follow-up by the healthcare team is essential in ensuring medication compliance and patient safety.
When a clinician initiates duloxetine therapy, it does not take place in isolation. The pharmacist should perform a thorough medication reconciliation to preclude any drug interactions, and verify that dosing is appropriate. A psychiatric health specialist nurse will be able to assist with patient counseling regarding adverse effects, administration, and monitor the patient on follow-up visits. Should the pharmacist or nurse see anything of concern, they will report it to the prescriber promptly. Any social workers or other mental health counselors also need to be included in the sharing of information, as well. This type of interprofessional team paradigm can help bring about optimal patient outcomes with minimal adverse events. [Level V]
|||Cipriani A,Koesters M,Furukawa TA,Nosè M,Purgato M,Omori IM,Trespidi C,Barbui C, Duloxetine versus other anti-depressive agents for depression. The Cochrane database of systematic reviews. 2012 Oct 17; [PubMed PMID: 23076926]|
|||Li X,Zhu L,Zhou C,Liu J,Du H,Wang C,Fang S, Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis. PloS one. 2018; [PubMed PMID: 29558528]|
|||Detke MJ,Wiltse CG,Mallinckrodt CH,McNamara RK,Demitrack MA,Bitter I, Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2004 Dec; [PubMed PMID: 15589385]|
|||Kiso T,Moriyama A,Furutani M,Matsuda R,Funatsu Y, Effects of pregabalin and duloxetine on neurotransmitters in the dorsal horn of the spinal cord in a rat model of fibromyalgia. European journal of pharmacology. 2018 May 15; [PubMed PMID: 29530591]|
|||White C,Kwong WJ,Armstrong H,Behling M,Niemira J,Lang K, Analysis of Real-World Dosing Patterns for the 3 FDA-Approved Medications in the Treatment of Fibromyalgia. American health [PubMed PMID: 30464796]|
|||Wohlreich MM,Mallinckrodt CH,Prakash A,Watkin JG,Carter WP, Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depression and anxiety. 2007; [PubMed PMID: 16845641]|
|||Andrade C, The safety of duloxetine during pregnancy and lactation. The Journal of clinical psychiatry. 2014 Dec; [PubMed PMID: 25551238]|
|||American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2019 Jan 29; [PubMed PMID: 30693946]|
|||Alibegović A,Kariž S,Volavšek M, Fatal overdose with a combination of SNRIs venlafaxine and duloxetine. Forensic science, medicine, and pathology. 2019 Feb 22; [PubMed PMID: 30796754]|